2023年11月27日 · What is Ryzneuta? Ryzneuta (Efbemalenograstim alfa) is a granulocyte colony-stimulating factor (G-CSF) used to lower the risk of infection when you have neutropenia, low levels of a type of white blood cells caused by cancer chemotherapy.

2025年1月9日 · RYZNEUTA is given as an injection under your skin (subcutaneous injection) by a healthcare provider. RYZNEUTA should be injected at least 24 hours after your dose of chemotherapy and at least 14 days before your next dose of chemotherapy.

Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia. [1] It is a leukocyte growth factor. [ 1 ] It is given by subcutaneous injection.

RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer...

2024年1月26日 · Ryzneuta is a medicine that stimulates the production of white blood cells. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving cytotoxic chemotherapy (medicines to treat cancer by killing cells).

2024年3月15日 · RYZNEUTA is a prescription drug that is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid...

Efbemalenograstim alfa-vuxw belongs to a class of medicines called granulocyte colony-stimulating factors (G-CSF). G-CSF helps the body make more white blood cells. White blood cells help fight infection in your body. This drug is given as an injection under the skin (subcutaneously). View the fact sheet about Efbemalenograstim alfa-vuxw (PDF).

Used to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

2023年12月4日 · Ryzneuta (efbemalenograstim alfa-vuxw) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Ryzneuta is a long-acting granulocyte colony-stimulating factor (G-CSF). The efficacy of Ryzneuta was established in two randomized, controlled studies.